Comparative analysis of the efficacy of Mobotinib and other targeted drugs

Mobocertinib (also known as Mobocertinib) is a new oral EGFRtyrosine kinase inhibitor (TKI) specifically designed to treat patients with EGFR Patients with non-small cell lung cancer (NSCLC) with Exon20insertion mutations. Patients with this type of mutation have limited response to traditional EGFR-targeted drugs (such as erlotinib, gefitinib, and osimertinib). Therefore, the emergence of mobotinib provides a new treatment option for this small but urgent clinical need.

Compared with first- and third-generation EGFR-TKIs, mobotinib shows higher specificity and inhibitory ability against Exon20 insertion mutations. For example, osimertinib is less active in this type of mutation, while mobotinib has demonstrated higher objective response rates (ORR) and disease control rates (DCR) in clinical studies. According to research data, mobotinib has the potential to reduce EGFR in patients who have previously received chemotherapy In patients with Exon20 mutations, the ORR can reach 28%, and the median progression-free survival (PFS) is about 7.3 months, which is better than standard chemotherapy regimens.

In addition, another new drug, amivantinib (Amivantamab), which targets EGFR Exon20 mutations, is a bispecific antibody and is also making progress in this field. Compared with mobotinib, although amifantinib has similar clinical efficacy, it is an intravenous infusion drug with a more complex medication method and a slightly different adverse reaction spectrum. Mobotinib, as an oral preparation, has obvious advantages in convenience of use and is especially suitable for patients who require long-term maintenance treatment.

Overall, mobotinib has filled the gap in traditional TKI treatment in the field of Exon20insertion mutation non-small cell lung cancer. Compared with other targeted drugs, it is more targeted, has clear efficacy, and has good oral compliance. But at the same time, we need to be wary of its common adverse reactions such as diarrhea, rash, stomatitis, etc. During use, patients should follow up regularly under the guidance of a professional doctor to ensure a balance between treatment safety and effectiveness.

References:https://en.wikipedia.org/wiki/Mobocertinib